Invest Now
Samco securities limited
Samco Star Rating Ads

Astrazeneca Pharma India Ltd

₹ 6,657.45 -89.90 (-1.33%)

Updated on 17-09-2024 4:40 PM

Stock Rating

Pros 3

 

Cons 4

Price Performance

  • Day's Low
  • ₹6,603.55
  • Day's High
  • ₹6,749.80
₹ 6,657.45
  • 52-w low
  • ₹4,311
  • 52-w high
  • ₹7,572.20
6,657.45
  • Day's open
    ₹6,749.80
  • Previous close
    ₹6,747.35
  • VWAP
    ₹6,669.67
  • Lower price band
    ₹5,397.90
  • Upper price band
    ₹8,096.80

Today's Market Action

The last traded share price of Astrazeneca Pharma India Ltd was 6,657.45 down by -1.33% on the NSE. Its last traded stock price on BSE was 6,683 down by -1.10%. The total volume of shares on NSE and BSE combined was 6,820 shares. Its total combined turnover was Rs 4.55 crores.

Medium and Long Term Market Action

Astrazeneca Pharma India Ltd hit a 52-week high of 7,572.20 on 04-07-2024 and a 52-week low of 4,311 on 27-09-2023. The stock price of Astrazeneca Pharma India Ltd is up by 1% over the last one month. It is up by 46.62% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

  • Market Cap (Cr): 16868

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About

Data not available.

FAQ's

What is Share Price of Astrazeneca Pharma India Ltd?

What is the Market Cap of Astrazeneca Pharma India Ltd?

What is PE Ratio of Astrazeneca Pharma India Ltd?

What is PB Ratio of Astrazeneca Pharma India Ltd?

What is the CAGR of Astrazeneca Pharma India Ltd?

How to Buy Astrazeneca Pharma India Ltd Share?

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

  • Above Average Sustainable RoE
    The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
  • Asset Light Business
    The company operates a great asset light business with a high Asset turnover ratio of 17.87. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
  • Zero Debt
    The company has almost nil to negligible debt to equity ratio of 0.01. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only 11.86% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Poor Capital Allocation
    The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 93.78 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 116 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(17/09/2024)
Stock Valuation
Green line
96
100.00%
100.00% People are bullish about Astrazeneca Pharma India Ltd
0.00%
0.00 % People are bearish about Astrazeneca Pharma India Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Astrazeneca Pharma India Ltd

₹ 6,657.45 -89.90 (-1.33%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon